Written by Dr. Piercecchi, MD, founder of The Men’s Clinic for Wellness & Vitality.
This article is for general educational purposes only. It is not medical advice, diagnosis, or treatment, and reading it does not create a physician-patient relationship.
This SITREP is intentionally long and detailed because GLP-1 medications deserve more than a quick take. Start with the BLUF if you want the short version, or use the table of contents below to jump directly to the sections that matter most to you. The goal is to separate the real medicine from the marketing, the hype, and the fear, and to explain how these drugs should actually be understood and prescribed.
Table of Contents
BLUF: The Short Version
If you read nothing else, read this. This is the whole argument in one section. Everything that follows this BLUF is the evidence and the clinical detail behind it.
This SITREP is written to cut through both the hype and the fear. Some people talk about GLP-1s as if they are miracle drugs that ask nothing of the patient: take the injection and change nothing else. Others talk about them as if they are dangerous pharmaceutical poison. Both views are wrong. Some of the criticism is legitimate and worth taking seriously, but much of it is poppycock. By analyzing the evidence and combining it with clinical experience, we can separate real clinical concerns from overblown claims and explain how these medications should actually be used.
Regardless of your stance on these drugs, both sides agree that GLP-1s work. Semaglutide and tirzepatide are the two dominant drugs in this class today. They are branded and sold as Ozempic, Wegovy, Mounjaro, and Zepbound, and produce weight loss no previous drug has matched. In the right patient, semaglutide also reduces real cardiovascular risk, and tirzepatide has a legitimate role in obesity-related sleep apnea. Those claims are not hype.
But a drug that “works” and a drug that helps a man become healthier are not always the same thing. A man can lose thirty pounds on one of these medications and still end up weaker, less fit, and less healthy than he was before, especially if that weight loss includes significant muscle loss. That is one of the most important criticisms that we will discuss later.
In short: GLP-1 medications are legitimate, powerful medical tools. They are not fake wellness products, and they are not inherently bad, despite what many so-called experts might suggest. But their value depends on whether they improve a man’s actual health rather than simply lowering his scale weight. Used correctly, they can be real medicine. Used carelessly, they can become a shortcut that produces a less healthy man.
What Are GLP-1 Medications?
GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut releases after you eat. One of its jobs is to help regulate blood sugar. Another is to send signals to your brain to tell you if you are full or hungry. GLP-1 medications are engineered to activate that same pathway, which is why they can reduce appetite and caloric intake so effectively. Semaglutide is a GLP-1 receptor agonist. Tirzepatide works differently. It activates two hormone pathways instead of one: GLP-1 and GIP. GIP stands for glucose-dependent insulinotropic polypeptide, another gut-derived hormone released after eating. That dual GLP-1/GIP activity is part of why tirzepatide tends to produce greater weight loss than semaglutide. In SURMOUNT-5, the head-to-head trial, tirzepatide produced about 20.2% weight loss versus about 13.7% for semaglutide over 72 weeks.⁶
Before going further, it is worth clarifying one issue, because peptides have become a major marketing tool in the longevity space. Many products sold online or through longevity clinics are promoted as peptides with vague promises of increasing growth hormone, burning fat, improving recovery, or slowing aging. But a peptide isn’t a magic drug; it’s simply a short chain of amino acids. GLP-1-based medications, like semaglutide and tirzepatide, are peptide-based drugs, but they should not be lumped together with the peptides commonly marketed in wellness and gray-market circles. These are FDA-approved medications with defined dosing, large human clinical trials, measured clinical outcomes, and rigorous safety evaluation. That does not make them risk-free, but it does make the comparison misleading. Semaglutide and tirzepatide should be evaluated as regulated medications supported by clinical trial data, not dismissed or promoted simply because they fall under the broad biochemical category of peptides.
Back to All Blogs